Good MorningEquity markets held their ground on Wednesday following a round of mixed earnings reports. News from companies like Netflix, Abbott Laboratories, and big banks left the market wanting more. While many are reporting better than expected, the results are offset by uncertainty and have the market in a wait-and-see mode. More reports are due on Thursday that could tip the balance in favor of bulls or bears.
The S&P 500 remains below resistance at critical levels. If the market can not get above 4,150 and stay there, it will risk another significant decline. The true risk is inflation and the Fed, which was highlighted in the Beige Book report. According to the Fed, activity is down in most regions, although inflation remains high and above target. The takeaway is that activity is declining, and the FOMC can be counted on to keep interest rates high until activity slows enough to tame inflation. Featured: Regarding your MarketBeat Membership (Ad) 
|
Technology | |
ASML (NASDAQ: ASML) reported its first quarter 2023 earnings this morning as the Dutch semiconductor equipment manufacturer gears up for what the year may hold for the semiconductor industry. ASML shares are trading lower today, selling off by as much as 3.65% after the announcement. Companies lik... Read the Full Story |
|
From Our Partners | | Wall Street spends millions on supercomputers and analyst teams to forecast stock prices. Now a new predictive AI is giving Main Street investors access to the same edge - forecasting over 2,334 stocks up to 21 days into the future.
Built on a principle similar to hurricane tracking models, this AI has unlocked an investing approach that reportedly beats buy-and-hold five to one. You don't need to be a hedge fund or a millionaire to use it. | | Watch the free Predictive AI demo and get five stock picks today |
|
Aerospace | |
Lockheed Martin Corporation (NYSE: LMT) scored a double beat in its first-quarter earnings report. And analysts are impressed. The morning after the announcement, Citigroup, Inc. (NYSE: C) and Credit Suisse Group AG (NYSE: CS) boosted their price targets for LMT stock to $579 and $550, respectivel... Read the Full Story |
|
Auto/Tires/Trucks | |
When Mullen Automotive (NASDAQ: MULN) began its aggressive strategy in the summer of 2022, it caught the market’s attention. A series of more-than-positive news events starting with the acquisition of Bollinger Motors and ending with the recently announced deliveries of vans, was enough to g... Read the Full Story |
|
From Our Partners | | On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. Marjorie Taylor Greene claims the bill contains 'the entire setup, groundwork and infrastructure to move from cash to digital currency.'
If the legislation becomes law, the implications for how Americans store and control their money could be significant. There may be a limited window to act before it takes effect. | | Learn what steps you can take to protect your wealth before this becomes law |
|
Medical | |
It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. Med-tech companies like Intuitive Surgical (NASDAQ: ISRG), Boston Scientific (NYSE: BSX) and DexCom (NASDAQ: DXCM) have seen an increase in analyst interest driven by results and outlook. What is surprising is that Abb... Read the Full Story |
|
Technology | |
Shares of Okta (NASDAQ: OKTA) are down from their peaks along with most of the rest of the cyber-security industry, but a bottom is in progress, and a reversal is at hand. Not only is the upcoming earnings report an opportunity for outperformance but there is a devil in the details regarding the a... Read the Full Story |
|
From Our Partners | | Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening.
The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | | Watch the free briefing and see the three steps to prepare today |
|
Consumer Discretionary | |
A 12% slide in yesterday’s after-hours session might have been about the last thing Netflix Inc (NASDAQ: NFLX) investors expected, let alone wanted. But such was the initial reaction to the streaming giant’s Q1 earnings which were released after the bell. While shares managed to recoup... Read the Full Story |
|
Markets | |
United Airlines (NASDAQ: UAL) shares have seen increased volatility in the after-market trading hours after reporting first quarter 2023 earnings results. The stock reached a high of $44.75 immediately after the earnings report and followed a swift bounce back toward $43. Investors can attempt to ... Read the Full Story |
|
Consumer Discretionary | |
It’s true, those workout clothes from Lululemon Athletic Inc. (NASDAQ: LULU) are pricey and trendy, but the company has proven itself to be more than just the flavor of the month. Sales continue to grow, and the company continues to innovate, even as other clothing and athletic gear trends c... Read the Full Story |
|
Consumer Discretionary | |
There was a time, known as June 2020, when you could check into a hotel and essentially have the place to yourself. But those days are long gone, and chains InterContinental Hotels Group Plc (NYSE: IGH), Hilton Worldwide Holdings Inc. (NYSE: HLT) and Hyatt Hotels Corp. (NYSE: H) are all up on a ye... Read the Full Story |
|
Basic Materials | |
It’s been a heck of a month for Teck Resources Limited (NYSE: TECK). On April 3rd, the Canadian mining company rejected a hostile $22.5 billion takeover bid from Swiss commodity company Glencore. Presented a week prior, the private proposal had visions of spinning off the combined companies&... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. | | View Today's Stock Pick |
|
